Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.

导出 OA

翻译打印收藏纠错

作者： Cinzia,Lanzi ^[1] ; Enrica,Favini ^[1] ; Laura,Dal Bo ^[1] ; Monica,Tortoreto ^[1] ; Noemi,Arrighetti ^[1] ; Nadia,Zaffaroni ^[1] ; Giuliana,Cassinelli ^[2]

作者单位： Department of Applied Research and Technological Development, Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133, Milan, Italy. ^[1] Department of Applied Research and Technological Development, Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133, Milan, Italy. giuliana.cassinelli@istitutotumori.mi.it. ^[2]

关键词 EGR1 ERK FK228 Heparanase inhibitor Histone deacetylase inhibitor SAHA SST0001 Synovial sarcoma

主题词动物(Animals);葡糖醛酸糖苷酶(Glucuronidase);组蛋白脱乙酰基酶抑制剂(Histone Deacetylase Inhibitors);人类(Humans);小鼠(Mice);肉瘤, 滑膜(Sarcoma, Synovial);增量调节(Up-Regulation)

DOI 10.1186/s13046-021-02150-y

PMID 34857011

发布时间 2024-04-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交